A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors
{{output}}
Mutant RAS proteins are among the most prevalent drivers of human cancer, and the glycine to aspartic acid mutation at codon 12 (G12D) is the most common variant. Mutation-selective covalent inhibitors spare RAS in healthy tissue and enable extended pharmacody... ...
